Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market

Executive Summary

Novartis' Lek generic division is following Mylan with an "at risk" launch of generic omeprazole

You may also be interested in...



Omeprazole Generic Will Stay: Schwarz Does Not Infringe Prilosec Patent

Schwarz' omeprazole does not infringe AstraZeneca's Prilosec patents because the generic does not contain an alkaline reacting compound, a D.C. federal appeals court affirmed Dec. 11

Omeprazole Generic Will Stay: Schwarz Does Not Infringe Prilosec Patent

Schwarz' omeprazole does not infringe AstraZeneca's Prilosec patents because the generic does not contain an alkaline reacting compound, a D.C. federal appeals court affirmed Dec. 11

Schwarz Coping With Omeprazole Competition; Parcopa Is Next Launch

Schwarz' levodopa/carbidopa rapid dissolve formulation Parcopa will be the company's first attempt to convert its omeprazole windfall into a larger presence in the U.S. market

Related Content

UsernamePublicRestriction

Register

PS042357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel